Dutch human gene therapy specialist uniQure (Nasdaq: QURE) has made several new executive appointments.
The company says the changes are aimed at “furthering expansion in the United States and adding additional expertise in gene therapy research, development, operations, manufacturing and commercial readiness.”
uniQure has appointed Scott McMillan as chief operating officer, based in Massachusetts. Dr McMillan joins the company with more than 25 years of biotechnology experience and will be responsible for all current Good Manufacturing Process (cGMP) activities at uniQure and all product development functions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze